GSK : Japan's Ministry of Health, Labour and Welfare approves GSK's Arexvy, the country's first respiratory syncytial virus (RSV) vaccine for older adults -September 25, 2023 at 02:07 am EDT

Arexvy's approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time, including those living with underlying medical conditions who are...

Related Keywords

Japan ,Canada ,United Kingdom ,Japanese ,Tony Wood ,European Commission ,Japan Ministry Of Health ,Statistics Bureau Home Page Population Estimates Monthly ,Centers For Disease ,Antigenics Inc ,Saponiqx Inc ,Agenus Inc ,Drug Administration ,Chief Scientific Officer ,Adult Respiratory Syncytial Virus ,New England Journal ,Product Information ,Annual Report ,Disease Control ,Older Adults ,Chronic Medical ,Accessed March ,Markets ,